{"id":"W3013704572","doi":"10.1158/1538-7445.sabcs19-pd4-01","title":"Abstract PD4-01: First-line veliparib plus carboplatin/paclitaxel in patients with HER2-negative advanced/metastatic g<i>BRCA</i>-associated breast cancer: Planned subgroup analysis from the phase 3 BROCADE3 trial","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Veliparib; Medicine; Internal medicine; Metastatic breast cancer; Carboplatin; PARP inhibitor; Placebo; Breast cancer; Hazard ratio; Population; Oncology; Clinical endpoint; Cancer; Chemotherapy; Surgery; Randomized controlled trial; Confidence interval; Pathology; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006568893,0.0005748168,0.001411237,0.0003504583,0.0003850992,0.00009743234,0.0006126622,0.0001780538,0.001217667],"category_scores_gemma":[0.000647392,0.0004085094,0.0002530288,0.004371353,0.0005758779,0.0003903841,0.0001619339,0.001818245,0.00002567662],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002218641,"about_ca_system_score_gemma":0.001269604,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.01967078,"about_ca_topic_score_gemma":0.02344455,"domain_scores_codex":[0.9940756,0.0004159423,0.0008965442,0.001194358,0.002136333,0.0012812],"domain_scores_gemma":[0.9959055,0.001441572,0.000452147,0.000720464,0.0008791482,0.0006011332],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.69775,0.002766991,0.2042657,0.0003296087,0.008551061,0.0002512424,0.012385,0.02368125,0.001043063,0.00001548039,0.001281335,0.04767935],"study_design_scores_gemma":[0.3057693,0.004281536,0.6787453,0.001230619,0.001359829,0.000001950824,0.002634918,0.002344655,0.001071242,0.0002268964,0.001442352,0.0008914234],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9797416,0.0018951,0.0001170056,0.009719476,0.0001668387,0.003208244,0.004960913,0.0001019128,0.00008887143],"genre_scores_gemma":[0.9956532,0.0004688863,0.0001619794,0.000921022,0.0005913693,0.001292598,0.0006870403,0.0001240318,0.00009983977],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4744796,"threshold_uncertainty_score":0.9998367,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06192788902987865,"score_gpt":0.3858429995150197,"score_spread":0.323915110485141,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}